The temptation is to skip the low-dose titration phase, reasoning that GLP-1 receptor adaptation has already occurred
Acta Pharm Sinica B 13(5):2291 Faillie JL, Yin H, Yu OH, Herrero A, Altwegg R, Renoux C, Azoulay L (2022) Incretin-Based drugs and risk of intestinal obstruction among patients with type 2 diabetes
We on the front lines are seeing the very real risks of obesity right now, and we should not deprive patients of medications that can reduce or even remove those risks entirely, she says
A class of injectable medications known as GLP-1 agonists, sold in Canada under the brand names Ozempic and Wegovy, are approved to treat Type 2 diabetes and obesity, respectively
Association of antidiabetic therapies with lower extremity amputation, mortality and healthcare cost from a nationwide retrospective cohort study in Taiwan